- Expanded clinical validation data demonstrate Percepta Nasal Swab test performance across nodule sizes and cancer stages in early lung cancer assessment -

- Findings reinforce value of Percepta GSC and Envisia GC in clinical decision-making and patient care -

Veracyte, Inc. (Nasdaq: VCYT) announced that four abstracts highlighting the clinical impact of the company’s genomic diagnostic tests for lung cancer and interstitial lung disease (ILD) will be presented at the American College of Chest Physicians (CHEST) Annual Meeting 2021, being held virtually October 17-20, 2021.

The abstracts include new data from an expanded clinical validation study which demonstrate the ability of Veracyte’s Percepta Nasal Swab test to determine cancer risk in patients with lung nodules found on CT scans – across lung nodule sizes, lung cancer stages and patients’ prior-cancer status. Veracyte developed the novel noninvasive test to help physicians more accurately, quickly and confidently determine which patients can be safely directed to routine monitoring and which should proceed to further diagnostic work-up and treatment as needed.

“The Percepta Nasal Swab is a key component of Veracyte’s lung cancer portfolio and expands our ability to answer clinical questions across the patient journey in lung cancer,” said Marc Stapley, Veracyte’s chief executive officer. “Collectively, the new data that will be presented at this year’s CHEST meeting demonstrate the power of our cutting-edge genomic science and technology to help physicians and patients make better, faster and more confident care decisions in serious lung diseases.”

Additional abstracts to be presented at the CHEST meeting provide further evidence that Veracyte’s Percepta and Envisia classifiers deliver valuable genomic information that helps guide patient care in lung cancer and ILDs (including idiopathic pulmonary fibrosis), respectively.

Following are details of the four abstracts:

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Nasal Swab, Percepta Genomic Sequencing Classifier and Envisia Genomic Classifier. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its Percepta Nasal Swab Test can significantly improve the early assessment of lung cancer and assist healthcare providers in guiding patients regarding treatment options. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005393/en/